Bio-Rad Laboratories EBITDA 2010-2022 | BIO.B

Bio-Rad Laboratories annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Bio-Rad Laboratories EBITDA for the quarter ending March 31, 2022 was $0.143B, a 42.2% increase year-over-year.
  • Bio-Rad Laboratories EBITDA for the twelve months ending March 31, 2022 was $0.532B, a 21.61% increase year-over-year.
  • Bio-Rad Laboratories 2021 annual EBITDA was $0.489B, a 19.1% increase from 2020.
  • Bio-Rad Laboratories 2020 annual EBITDA was $0.411B, a 78.94% increase from 2019.
  • Bio-Rad Laboratories 2019 annual EBITDA was $0.23B, a 322.24% decline from 2018.
Bio-Rad Laboratories Annual EBITDA
(Millions of US $)
2021 $489
2020 $411
2019 $230
2018 $-103
2017 $119
2016 $56
2015 $167
2014 $150
2013 $169
2012 $264
2011 $305
2010 $284
2009 $231
Bio-Rad Laboratories Quarterly EBITDA
(Millions of US $)
2022-03-31 $143
2021-12-31 $107
2021-09-30 $157
2021-06-30 $125
2021-03-31 $101
2020-12-31 $175
2020-09-30 $110
2020-06-30 $52
2020-03-31 $74
2019-12-31 $59
2019-09-30 $57
2019-06-30 $56
2019-03-31 $57
2018-12-31 $-227
2018-09-30 $71
2018-06-30 $44
2018-03-31 $44
2017-12-31 $56
2017-09-30 $74
2017-06-30 $35
2017-03-31 $60
2016-12-31 $-21
2016-09-30 $67
2016-06-30 $60
2016-03-31 $60
2015-12-31 $59
2015-09-30 $33
2015-06-30 $40
2015-03-31 $34
2014-12-31 $51
2014-09-30 $33
2014-06-30 $46
2014-03-31 $20
2013-12-31 $52
2013-09-30 $29
2013-06-30 $53
2013-03-31 $35
2012-12-31 $71
2012-09-30 $66
2012-06-30 $73
2012-03-31 $54
2011-12-31 $96
2011-09-30 $74
2011-06-30 $68
2011-03-31 $67
2010-12-31 $78
2010-09-30 $75
2010-06-30 $68
2010-03-31 $63
2009-12-31 $56
2009-09-30 $67
2009-06-30 $56
2009-03-31 $51
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.121B $2.923B
BIO-RAD LABORATORIES, INC. manufactures and supplies to life sciences research, healthcare, analytical chemistry, semiconductor and other markets a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00